Algeta schedules Third Quarter 2009 Presentation
(Thomson Reuters ONE) - Oslo, Norway, 04 November 2009 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, will announce its thirdquarter 2009 results on Friday, 13 November 2009. A presentation toinvestors, analysts and the press will take place in Oslo at 08:15CET. Algeta's President and CEO Andrew Kay, CTO Thomas Ramdahl andCFO ÿystein Soug will present.An international conference call will take place at 14:30 CET(details below). Andrew Kay, Thomas Ramdahl and ÿystein Soug willparticipate.The presentation will take place at 08:15 CET at:Hotel ContinentalStortingsgaten 24/260117 OsloNorway.Breakfast will be served from 07:45 CET.To participate in the conference call, please dial the appropriatenumber below five minutes prior to the call:800 80 119 (in Norway)+47 23 00 04 00 (from abroad).The results report and the presentation will be made available onwww.algeta.com in the Investors section from 08:00 CET.To access the replay, please dial +47 67 89 40 91. Enter account no.1428 followed by #, then press 1, conference no. 428 followed by #.Press 1 to play. A replay version of the conference call will also beavailable at www.algeta.com. ###For further information, please contactAndrew Kay, CEOÿystein Soug, CFO +47 23 00 67 42 / +47 484 01 360 (mob) +47 23 00 79 84 / +47 906 56 525 (mob) post(at)algeta.comDr Mark Swallow / David Dible +44 (0) 207 638 9571/ Helena Galilee mark.swallow(at)citigatedr.co.ukCitigate Dewe RogersonAbout AlgetaAlgeta ASA is a cancer therapeutics company built on world-leading,proprietary technology. Algeta is developing a new generation oftargeted cancer therapeutics (alpha-pharmaceuticals) that harness theunique characteristics of alpha particle emitters and are potent,well-tolerated and convenient to use.Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based onradium-223), has blockbuster potential for treating bone metastasesarising from multiple major cancer types, owing to its bone-targetingnature, potent efficacy (therapeutic and palliative) and benign,placebo-like safety profile. Development of Alpharadin is mostadvanced targeting bone metastases resulting from hormone-refractoryprostate cancer (HRPC), and it entered an international phase IIIclinical trial (ALSYMPCA) in mid-2008 based on compelling clinicalresults from a comprehensive phase II program.Algeta's strategy is to launch Alpharadin as a first or second linetreatment for cancer patients with bone metastases either alone or incombination with current standard of care therapies, therebymaximizing its commercial potential.Algeta is also developing other technologies for deliveringalpha-pharmaceuticals. These include microparticles, liposomes, andmethods to enhance the potency of therapeutic antibodies and othertumor-targeting molecules by linking them to the alpha particleemitter thorium-227. The Company is headquartered in Oslo, Norway,and was founded in 1997. Algeta listed on the Oslo Stock Exchange inMarch 2007 (Ticker: ALGETA).Alpharadin and Algeta are trademarks of Algeta ASA.Forward-looking StatementThis news release contains forward-looking statements and forecastsbased on uncertainty, since they relate to events and depend oncircumstances that will occur in the future and which, by theirnature, will have an impact on results of operations and thefinancial condition of Algeta. There are a number of factors thatcould cause actual results and developments to differ materially fromthose expressed or implied by these forward-looking statements.Theses factors include, among other things, risks associated withtechnological development, the risk that research & development willnot yield new products that achieve commercial success, the impact ofcompetition, the ability to close viable and profitable businessdeals, the risk of non-approval of patents not yet granted anddifficulties of obtaining relevant governmental approvals for newproducts. ###http://hugin.info/134655/R/1352496/327226.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 04.11.2009 - 10:10 Uhr
Sprache: Deutsch
News-ID 7887
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 363 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta schedules Third Quarter 2009 Presentation"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
